3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation
With this pharma company trading for less than 10 times earnings, the market remains very uncertain about its stock and looming patent cliff.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.